Histórico de receita, lucros e fluxo de caixa das demonstrações financeiras oficiais.
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Ver gráficos interativos e demonstrações completas → Modelo de avaliação (DCF) →
| Demonstração de resultados | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receita total | $79.7B | $65.2B | $45.0B | $34.1B | $28.5B | $28.3B | $24.5B | $22.3B | $21.5B | $20.0B | $21.2B | $20.0B | $19.6B | $23.1B | $22.6B | $24.3B | $23.1B | $21.8B | $20.4B | $18.6B | $15.7B |
| Lucro bruto | $66.9B | $54.6B | $36.6B | $27.0B | $21.9B | $21.0B | $19.1B | $17.6B | $16.8B | $15.5B | $15.5B | $14.9B | $14.7B | $18.2B | $17.8B | $19.2B | $18.7B | $17.6B | $16.0B | $14.4B | $12.1B |
| Margem Bruta % | 84.0% | 83.8% | 81.3% | 79.2% | 76.8% | 74.2% | 77.7% | 78.8% | 78.2% | 77.7% | 73.1% | 74.8% | 74.9% | 78.8% | 78.8% | 79.1% | 81.1% | 80.5% | 78.5% | 77.2% | 77.4% |
| Resultado Operacional (EBIT) | $35.0B | $29.7B | $17.5B | $10.8B | $8.7B | $7.9B | $7.2B | $6.0B | $6.0B | $4.2B | $3.9B | $3.6B | $3.3B | $5.5B | $5.0B | $6.3B | $6.8B | $6.4B | $5.5B | $4.8B | $4.1B |
| % de margem operacional | 43.9% | 45.6% | 38.9% | 31.6% | 30.3% | 28.0% | 29.4% | 26.9% | 28.0% | 21.3% | 18.2% | 18.0% | 17.0% | 24.0% | 22.2% | 26.0% | 29.3% | 29.2% | 27.1% | 25.8% | 26.3% |
| Resultado líquido | $26.7B | $20.6B | $10.6B | $5.2B | $6.2B | $5.6B | $6.2B | $8.3B | $3.2B | ($204M) | $2.7B | $2.4B | $2.4B | $4.7B | $4.1B | $4.3B | $5.1B | $4.3B | ($2.1B) | $3.0B | $2.7B |
| Margem Líquida % | 33.5% | 31.7% | 23.5% | 15.4% | 21.9% | 19.7% | 25.2% | 37.3% | 15.0% | -1.0% | 12.9% | 12.1% | 12.2% | 20.3% | 18.1% | 17.9% | 22.0% | 19.8% | -10.2% | 15.8% | 17.0% |
| EBITDA | $35.2B | $27.9B | $15.2B | $8.6B | $8.7B | $8.0B | $8.9B | $6.9B | $5.5B | $4.1B | $5.1B | $4.4B | $4.5B | $7.5B | $7.0B | $6.9B | $8.0B | $6.9B | $43M | $5.9B | $4.9B |
| Lucro por ação (EPS) | $29.80 | $22.98 | $11.71 | $5.80 | $6.57 | $5.85 | $6.47 | $8.69 | $3.13 | $-0.19 | $2.49 | $2.18 | $2.15 | $4.19 | $3.57 | $3.90 | $4.58 | $3.94 | $-1.89 | $2.71 | $2.45 |
| Ações em circulação (M) | 894M | 898M | 904M | 903M | 950M | 954M | 957M | 958M | 1,034M | 1,052M | 1,101M | 1,105M | 1,111M | 1,117M | 1,146M | 1,114M | 1,106M | 1,098M | 1,094M | 1,091M | 1,087M |
Fonte: relatórios públicos da empresa (SEC). Verifique no SEC EDGAR antes de confiar em qualquer número.
Balanços, fluxos de caixa, dados trimestrais e indicadores completos no visualizador interativo de LLY. /companies/us/LLY
As informações deste site são apenas educacionais e informativas; não constituem recomendação de investimento. Não publicamos preços-alvo nem recomendações.
About TickerBase · Data methodology & sources · Privacy · Terms